Hyperkalemia: Pathophysiology, ECG Diagnostic Markers, Emergency Management, and Dietary Protocols

Potassium (K+) represents the primary intracellular cation; roughly 98% of total body potassium resides within cells at concentrations of 140–150 mmol/L, whereas normal serum levels strictly range between 3.5 and 5.0 mmol/L. This profound transmembrane gradient, sustained by the electrogenic Na+/K+-ATPase pump, establishes the resting membrane potential across excitable tissues, including cardiac myocytes, skeletal muscle fibers, and neurons. Even subtle elevations above 5.5 mmol/L (mild hyperkalemia), and particularly levels exceeding 6.5 mmol/L (severe hyperkalemia), drastically compromise cardiac electrophysiology, predisposing patients to fatal ventricular arrhythmias, complete heart block, and asystolic arrest.

The predominant cause of hyperkalemia is impaired renal excretion secondary to acute kidney injury (AKI) or advanced chronic kidney disease (CKD stages G4–G5). Additional common culprits include pharmacotherapies targeting the renin-angiotensin-aldosterone axis (ACE inhibitors, ARBs, mineralocorticoid receptor antagonists like spironolactone), NSAIDs, and potassium-sparing diuretics. Clinical symptoms can be insidious or manifest as ascending muscle weakness, paresthesias, flaccid paralysis, and bradycardia. The 12-lead ECG is the cornerstone of clinical risk stratification. Serial ECG findings progress from tall, peaked, narrow-based "tented" T waves to PR interval prolongation, loss of P waves, QRS complex widening, and ultimately a fatal sine-wave pattern degenerating into ventricular fibrillation.

The acute management of severe hyperkalemia (>6.5 mmol/L or any ECG changes) relies on a three-phase intervention. Phase 1: Immediate cardioprotective membrane stabilization via intravenous administration of 10 mL of 10% calcium gluconate (acts within 1–3 minutes; does not lower serum potassium, but antagonizes electrophysiological cardiac excitability). Phase 2: Transcellular shift of potassium into cells using an IV infusion of 10 units of regular insulin alongside 50 mL of 40% dextrose, supplemented by high-dose nebulized beta-2 agonists (albuterol/salbutamol 10–20 mg). Phase 3: Total body potassium elimination utilizing loop diuretics (furosemide), modern gastrointestinal potassium binders (patiromer, sodium zirconium cyclosilicate / SZC), or emergent hemodialysis in refractory renal failure.

In chronic hyperkalemia, dietary potassium is clinically restricted to 2,000–3,000 mg (50–75 mmol) daily under nephrological supervision. Patients must strictly avoid high-potassium foods: dried fruits (apricots, raisins, dates), legumes, nuts, cocoa, dark chocolate, bananas, avocados, tomatoes and their purees/pastes, as well as salt substitutes formulated with potassium chloride (KCl). Safe low-potassium foundations include apples, blueberries, strawberries, cucumbers, cabbage, zucchini, white rice, and refined pasta. A mandatory culinary practice is vegetable potassium leaching (double boiling): peeling and dicing potatoes and vegetables, soaking them in abundant water for 2–4 hours, boiling, discarding the initial water, and completing cooking in fresh water, which removes up to 50–70% of potassium.